Humacyte Inc
Research Humacyte Inc (HUMA) on Bullrun: market cap USD 194.74M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHUMA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 194.74M
- Financial periodQ1 2026
- RevenueUSD 495.00K
- Net income-USD 97.59M
- Free cash flow-USD 25.28M
- Gross margin-1934.7%
Valuation Snapshot
latest market cap is USD 194.74M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.04M | -USD 40.83M | -USD 105.93M | -376.1% | -0.26 | USD 50.50M | USD 35.44M | USD 3.11M |
| FY2024 | USD 0 | -USD 148.70M | -USD 99.69M | n/a | -1.26 | USD 44.94M | USD 0 | -USD 52.67M |
| FY2023 | USD 0 | -USD 110.78M | -USD 75.59M | n/a | -1.07 | USD 80.45M | USD 18.91M | USD 13.55M |
| FY2022 | n/a | -USD 11.97M | -USD 72.18M | n/a | -0.12 | USD 149.77M | USD 50.97M | USD 116.93M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 194.74M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 185.28M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 656.64M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 294.15M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 217.58M | 6.6 | n/a | n/a |
| 2021 | 2021-12-31 | USD 746.78M | n/a | n/a | n/a |
About Humacyte Inc
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Humacyte Inc's market cap?
Humacyte Inc's market capitalization is USD 194.74M.
What does Humacyte Inc do?
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.